ArriVent licenses ADC MRG007 from Lepu Biopharma; upfront $47M, total potential $1.16B

ArriVent BioPharma, Inc.

Exclusive global rights outside Greater China for MRG007, a preclinical ADC targeting GI cancers.
Lepu Biopharma receives $47M in upfront and near-term milestones; eligible for up to $1.16B in total milestones plus tiered royalties.
First IND submission planned for first half 2025; initial focus on CRC, pancreatic, and other GI cancers.
ArriVent’s previously announced cash runway into 2026 remains unchanged despite upfront and R&D costs.
MRG007 showed robust antitumor activity and favorable therapeutic index in preclinical and IND-enabling studies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.